It is very uncertain whether the intervention changes cefixime (1 RCT; 38 participants) (very low certainty).
It is very uncertain whether the intervention changes cefonicid (1 RCT; 60 participants) (very low certainty).
It is very uncertain whether the intervention changes meropenem plus daptomycin (No direct RCT) (very low certainty).
It is very uncertain whether the intervention changes ofloxacin (No direct RCT) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with Variceal rebleeding episodes at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with reintervention at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes irreversible shunt occlusion at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with encephalopathy at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral changes nausea compared with intravenous acetylcysteine (very low certainty).
It is very uncertain whether oral changes vomiting compared with intravenous acetylcysteine (very low certainty).